ETV6 and myelodysplastic syndrome: Myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML) develop in approximately 48% of patients with FPD/AML and in 7% of cases of ANKRD26-RT; 21% of individuals with ETV6-RT will go on to develop acute lymphoblastic leukemia (ALL), whereas another 7% will suffer from AML, MDS, multiple myeloma, or polycythemia vera.